SHAREHOLDER ALERT: Robbins LLP Announces that BioMarin Pharmaceutical Inc. (BMRN) is Being Sued for Misleading Shareholders
SAN DIEGO--(BUSINESS WIRE)--$BMRN #BMN307--Shareholder rights law firm Robbins LLP announces that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) securities between January 13, 2020 and September 3, 2021, for violations of the Securities Exchange Act of 1934. BioMarin develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. One of its product candidates is BMN 307, an AAV5 mediated gene therapy, which is in a phase 1/2 clinical trial to normalize blood phenylalanine ("Phe") concentration levels in patients with phenylketonuria ("PKU"). The Company's Phearless Phase 1/2 study is evaluating BMN 307 in adults with PKU.
If you suffered a loss due to BioMarin Pharmaceutical Inc.'s misconduct, click here.
BioMarin Pharmaceutical Inc. (BMRN) Misled the Investing Public Regarding the Safety of its Product Candidate BMN 307
According to the complaint, during the relevant period, defendants overstated BMN 307's clinical and commercial prospects. Specifically, the defendants failed to disclose that BMN 307 was less safe than BioMarin had led investors to believe and that its safety profile made it likely that the FDA would place a clinical hold on the Phearless Phase 1/2 study.
On September 5, 2021, BioMarin issued a press release announcing "that the [FDA] placed a clinical hold on the BMN 307 Phearless Phase 1/2 study," which "is evaluating BMN 307, an investigational AAV5-phenylalanine hydroxylase (PAH) gene therapy, in adults with [PKU]." BioMarin advised investors that "[t]he FDA's clinical hold was based on interim safety findings from a pre-clinical, non GLP pharmacology study." On this news, shares of BioMarin stock declined $7.14 per share, or 8.4%, to close at $77.81 per share on September 7, 2021.
If you purchased shares of BioMarin Pharmaceutical Inc. (BMRN) between January 13, 2020 and September 3, 2021, you have until December 21, 2021, to ask the court to appoint you lead plaintiff for the class.
All representation is on a contingency fee basis. Shareholders pay no fees or expenses.
Contact us to learn more:
About Robbins LLP: A recognized leader in shareholder rights litigation, the attorneys and staff of Robbins LLP have been dedicated to helping shareholders recover losses, improve corporate governance structures, and hold company executives accountable for their wrongdoing since 2002. To be notified if a class action against BioMarin Pharmaceutical Inc. settles or to receive free alerts when corporate executives engage in wrongdoing, sign up for Stock Watch today.
Attorney Advertising. Past results do not guarantee a similar outcome.